Defence Therapeutics Inc. (DTCFF)

2.5643 0.0000 (0.00%) At close: 02:53PM EDT

Defence Therapeutics Inc.

1680 – 200 Burrard Street
Vancouver, BC V6C 3L6
Canada
514 947 2272
https://defencetherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Sebastien Plouffe	CEO, Pres & Director	63.34k	N/A	1972
Mr. Patrick Joseph Meagher C.A., CPA, CA, CPA	CFO & Director	41.46k	N/A	1986
Dr. Simon Beaudoin	Chief Technical Science Officer	N/A	N/A	1984
Dr. Moutih Rafei Ph.D.	VP of R&D and Director	N/A	N/A	1983
Ms. Carrie Cesarone	Corp. Sec.	N/A	N/A	1965

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its proprietary platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. The company focuses on developing dendritic cell cancer vaccines; protein-based vaccine formulation against COVID and infectious diseases; and antibody drug conjugates (ADC) products targeting various cancers. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.

Corporate Governance

Defence Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.